

Antiviral Therapeutics

Technologies, Companies & Markets

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

December 2017

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is the CEO and a consultant at Jain PharmaBiotech. Prof. Jain's 473 publications include 28 books (5 as editor + 23 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. His "Textbook of Gene Therapy" was translated into Chinese in 2000. Recent books include a Handbook of Nanomedicine (2008, Chinese edition published by Peking University Press in 2011, 3rd ed by Springer in 2017), Textbook of Personalized Medicine (2009; Japanese ed 2012; 2nd ed Springer 2015), Handbook of Biomarkers (2010; Chinese edition, Chemical Industry Press 2016, 2nd ed 2017), "Applications of Biotechnology in Cardiovascular Therapeutics" (2011), "Applications of Biotechnology in Neurology (2013)", and "Applications of Biotechnology in Oncology (2014)", all of which have been published by Springer.

**December 2017 (originally published in 2007 and continuously updated since then)
Copyright © 2017 by**

**Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland**

**Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	17
1. Introduction to Virology	19
Introduction	19
Evolution of viruses	19
Virus databases	19
A practical classification of viruses	19
The human virome	21
Viral genomics	21
Pathomechanism of viral diseases relevant to therapy	21
Intrinsic host defense against retroviruses	22
Interferon-induced B cell deletion in chronic viral infections.....	23
Drosha as an interferon-independent antiviral factor	23
Life cycle of virus as basis for antiviral approaches.....	23
Genetic switch in virus infections	24
Emerging viruses	25
Viral-induced cancer	26
Viral encephalitis	26
Brain's response to viral infections	27
Combination of antivirals with immunosuppression in viral encephalitis.....	27
Molecular diagnosis of viral diseases	28
Prophylaxis versus therapy.....	28
Economic impact of viral diseases	29
Historical landmarks in the development of antiviral therapies	29
2. Antiviral Approaches	31
Classification	31
Antiviral drug discovery and development.....	31
Antiviral drug targets – viral versus cellular	31
Antivirals based on double-stranded RNA activated caspase oligomerizer.....	33
Antimicrobial peptides	33
Human DDX3 protein as a target for developing broad spectrum antiviral agents.....	33
Immunological approaches.....	34
Basics of immune regulation in relation to viruses.....	34
<i>Effect of viruses on the immune system.....</i>	34
<i>Latent viral infections and the immune system</i>	35
Immunomodulating agents	35
<i>Amplification of innate immunity.....</i>	35
<i>Blocking the effects of thromboxane A2 on thromboxane receptor</i>	36
<i>Enhancers of immune system.....</i>	36
<i>Promoting immune-mediated clearance of a chronic viral infections.....</i>	36
<i>Immunoglobulins</i>	37
<i>Bovine lactoferrin.....</i>	37
<i>Quercetin.....</i>	38
Monoclonal antibodies	38
<i>Antibody production technologies.....</i>	39
<i>Bavituximab.....</i>	39
<i>Treatment of viral infection with radiolabeled MAbs.....</i>	39
<i>Limitations of MAbs and measures to overcome these</i>	40
Interferon-based approaches.....	40
Cholesterol-25-hydroxylase.....	41
Novel antiviral approaches	41
Phosphatidylethanolamine inhibitors as potential antivirals.....	41
Squalamine.....	41
Synthetic modified hypericin compounds.....	42
Targeting Toll-like receptors	42
<i>Potential and drawbacks of TLR-ligands in viral diseases</i>	43
Inhibition of viral transport from cytoplasm into the cell nucleus.....	43
Nitric Oxide based antiviral therapeutics	43
Amino acid cognate anticodon binding specificity.....	44
Antisense approaches to viral infections.....	44
Antisense oligonucleotides	44
Limitations of antisense oligonucleotides as antivirals.....	45
Phosphorodiamidate morpholino oligomers.....	46
Gene therapy for viral infections.....	46
RNAi	46
RNAi screens of viral genomes.....	47

RNAi for treatment of viral infections	47
Promise and pitfalls of RNAi gene therapy	48
Role of proteomics in virology	48
Interaction of proteins with viruses	49
Quantitative temporal viromics	49
Management of rapidly evolving pathogens	49
Personalized medicine and viral diseases	50
An integrated approach to viral diseases	50
Current problems and needs in antiviral therapy	50
Immunoinformatic approach to vaccine design for emerging infections	51
3. Vaccines for Virus Infections	53
Introduction	53
Types of vaccines.....	54
DNA vaccines	54
Live attenuated virus vaccines	55
mRNA vaccines.....	55
Nanotechnology-based vaccines.....	56
<i>Nanobead adjuvants.....</i>	<i>56</i>
Recombinant viral vaccines	56
SMART vaccines.....	57
Synthetic peptides as vaccines	57
Virally vectored vaccines.....	58
Virosomes.....	59
Vaccines based on reverse genetics.....	59
Virus-like particles	59
Routine vaccination in children against viral infections	60
Personalized vaccines.....	61
Limitations of vaccines	61
Neurological complications of vaccination.....	61
Expert opinion on antiviral vaccines	62
4. Role of Nanotechnology in Developing Antiviral Agents.....	63
Introduction	63
Study of interaction of nanoparticles with viruses.....	63
Exosomes and viral infections.....	64
Nanoparticle antiviral agents.....	64
Silver nanoparticles.....	64
Fullerenes	64
Nanoparticles mimic RNAi for treatment of viral infections.....	65
Nanoviricides	65
Role of micelles in nanopharmaceuticals	65
Some physicochemical characteristics common to polymeric micelles	66
Structure and function of nanoviricides	66
<i>Mechanism of action of NanoViricides</i>	<i>66</i>
<i>Advantages of NanoViricides.....</i>	<i>68</i>
5. Delivery of Antivirals	71
Introduction	71
Methods of delivery of antiviral agents.....	71
Local application of antivirals.....	71
Systemic delivery of of protein-polymer antiviral drugs.....	72
Controlled delivery of antivirals.....	72
Targeted delivery of antivirals	72
Delivery of antivirals to the brain across the blood-brain barrier	73
Antiviral vaccine delivery systems	73
Minicell vaccine delivery.....	73
Transnasal delivery of vaccines by Newcastle disease virus as vector	73
Transdermal delivery of vaccines	74
<i>Dissolvable microneedle array for vaccine delivery</i>	<i>74</i>
<i>Electroporation for administering DNA vaccines</i>	<i>74</i>
<i>HIV/AIDS vaccination by transdermal application</i>	<i>76</i>
<i>Microneedles for transdermal delivery of vaccines</i>	<i>76</i>
<i>Needle-free delivery of vaccines.....</i>	<i>76</i>
<i>Transdermal vaccines for influenza.....</i>	<i>77</i>
Use of nanotechnology for improving delivery of antivirals	78
Macrophage-based nanoformulated antiretroviral therapy	79
Improvement of antiviral vaccine delivery by nanotechnology.....	79
<i>Bacterial spores for delivery of vaccines.....</i>	<i>79</i>
<i>Chitosan-derived nanoparticles for vaccine delivery.....</i>	<i>79</i>
<i>Dendrimer-based intracellular delivery of antibodies.....</i>	<i>80</i>

<i>Gold nanorods for delivery of RNA immune activator molecules</i>	80
<i>Lipid nanoparticles for immunostimulatory RNA delivery</i>	80
<i>Liposomal antiviral vaccine preparations</i>	81
<i>Nanoparticles for DNA vaccines</i>	81
<i>Nanospheres for controlled release of viral antigens</i>	81
<i>Proteosomes™ as vaccine delivery vehicles</i>	82
<i>Polymeric micellae for delivery of DNA vaccine</i>	82
<i>"Smart" nanoparticles for delivery of vaccines</i>	82
Nanocoating for local viricidal effect	82
Delivery of gene-based antiviral drugs	83
Limitations of delivery of gene, RNAi and antisense therapies	83
Systemic delivery of NanoViricides	84
Concluding remarks on delivery of antiviral agents	84
6. Competitive Assessment of Antiviral Approaches	85
Introduction	85
An ideal antiviral agent	85
SWOT analysis	85
Concluding remarks	88
7. Influenza Viruses	89
Introduction	89
Clinical features of influenza	89
Colds due to rhinovirus	89
Effects of influenza on the respiratory system.....	90
Effect of avian influenza on the nervous system.....	90
Epidemiology	90
Supermap of avian influenza	90
Influenza A	91
Avian influenza affecting humans.....	91
<i>Human infection with a H7N9 Virus</i>	92
Human influenza versus avian influenza.....	92
H1N1 influenza	93
Immune system and influenza	94
Immune Epitope Database and Analysis Resources	95
Role of Tpl2 in antiviral host defense mechanisms.....	95
Anti-influenza approaches	96
Pharmaceuticals.....	96
Neuraminidase inhibitors	96
<i>Mechanism of action</i>	96
<i>Tamiflu</i>	97
<i>Zanamivir</i>	97
<i>CS-8958</i>	97
<i>Peramivir</i>	98
<i>Resistance to neuraminidase inhibitors</i>	99
<i>Adverse effects of neuraminidase inhibitors</i>	99
<i>Concluding remarks on neuraminidase inhibitors</i>	100
Other drugs for influenza	100
<i>Adamantanes</i>	100
<i>Probenecid</i>	101
Current recommendations for the use of antiviral agents for influenza	101
Vaccines	101
<i>Seasonal influenza vaccines</i>	101
<i>Live attenuated influenza vaccine vs. inactivated vaccine</i>	102
<i>Recombinant influenza vaccine</i>	103
<i>Vaccines for H1N1 influenza</i>	103
<i>Vaccines for H7N9 influenza</i>	104
Current status of influenza vaccines	104
<i>Current recommendations for influenza vaccination</i>	104
<i>Current status of vaccine preparedness against seasonal influenza</i>	105
<i>Current status of vaccine preparedness against H5N1</i>	105
Limitations, needs and challenges of influenza vaccines	106
<i>Limitations of current influenza vaccines</i>	106
<i>Needs of influenza vaccines</i>	106
<i>Problems with demand and supply of influenza vaccines</i>	107
<i>Problems with access to virus samples</i>	108
<i>FluVac project for development of pandemic influenza vaccine</i>	108
<i>Influenza vaccines for multiple strains of influenza</i>	108
<i>Quadrivalent influenza vaccine</i>	109
<i>Universal influenza vaccines</i>	109
<i>Future of influenza vaccines</i>	110

Application of new technologies for influenza vaccines	110
<i>Adjuvants</i>	111
<i>Cell culture-derived influenza vaccines</i>	112
<i>DNA vaccines for avian influenza</i>	113
<i>Epitope-based vaccines for influenza</i>	113
<i>Gene-based vaccines for influenza</i>	114
<i>Live attenuated vaccines</i>	114
<i>MABs for passive immunization against avian influenza</i>	114
<i>M2e-based human influenza A vaccine</i>	114
<i>RNA vaccines against influenza A</i>	115
<i>Pre-pandemic split antigen H5N1 vaccine</i>	115
<i>Recombinant-protein based influenza vaccines</i>	116
<i>Synthetic avian influenza vaccine</i>	117
<i>Viral vectors for influenza vaccination</i>	117
<i>Virus-like particles as influenza vaccines</i>	117
RNAi-based approaches	119
<i>Inhibition of influenza virus by siRNAs</i>	119
<i>Limitations of RNAi approach to influenza</i>	120
<i>Challenges and future prospects of siRNAs for influenza</i>	120
Antisense approaches.....	120
<i>NEUGENE® antisense for inhibition of multiple strains of influenza A</i>	121
Nanoviricides against influenza	121
Other innovative approaches	122
<i>Abatacept</i>	122
<i>Polymeric coatings to inactivate influenza virus</i>	122
<i>Cytotoxic therapy</i>	123
<i>Cyanovirin</i>	123
<i>Fludase</i>	123
<i>Multiferon®</i>	123
<i>Pyrrolidine dithiocarbamate</i>	124
<i>Value of antivirals in preventing spread of influenza after exposure</i>	124
<i>Resistance to influenza therapy and efforts to overcome it</i>	125
FLUCURE project.....	125
NIAID Centers of Excellence for research on pandemic influenza viruses.....	125
Research on influenza viruses at Bayer	126
Concluding remarks and future	126

8. AIDS/HIV	129
Introduction	129
Epidemiology	129
Current concepts of pathomechanisms	129
Decoding the structure of an entire HIV genome.....	130
Genetic basis of resistance against HIV.....	130
Host-pathogen interactions that regulate HIV-1 replication.....	130
Pathogenesis of AIDS	131
Visualization of the interaction of HIV-1 proteins with target cells	132
Viral latency in HIV	132
Complications of AIDS	133
AIDS and the nervous system	133
AIDS wasting syndrome.....	133
Coexistent HIV-1 and HSV-2	134
Coexistent hepatitis virus infections with HIV	134
<i>HIV and HBV</i>	134
<i>HIV and HCV</i>	134
Opportunistic infections in AIDS.....	135
<i>HIV and tuberculosis</i>	136
Current therapies.....	136
Aim of anti-HIV drugs.....	137
Nucleoside reverse transcriptase inhibitors.....	138
Non-nucleoside reverse transcriptase inhibitors	139
<i>Efavirenz</i>	139
<i>Etravirine</i>	139
Protease inhibitors	139
<i>Tipranavir</i>	139
<i>Darunavir</i>	139
Fusion inhibitors	140
<i>Enfuvirtide</i>	140
Impact of antiretroviral treatment on transmission of HIV.....	140
Preexposure prophylaxis against HIV.....	141
Postexposure prophylaxis against HIV	142
Antiretroviral therapy in early asymptomatic HIV infection	142

Limitations of current therapies.....	142
Adverse effects of antiretroviral therapy	143
Drug resistance in AIDS.....	144
Effect of interruption of HIV treatment.....	144
Reservoirs of HIV Infection.....	145
Persistence of low-level viremia in HIV-1 patients on retroviral therapy	145
Reconsideration of abandoned therapies for AIDS.....	145
Therapies in development.....	145
Drugs in development for HIV/AIDS	145
<i>NRTIs in development</i>	146
<i>NNRIs in development</i>	147
Novel protease inhibitors	147
<i>Overcoming HIV-1 resistance to PIs</i>	147
<i>PPL-100</i>	148
Entry inhibitors targeting CCR5 receptor	148
<i>Maraviroc</i>	149
<i>SP-01A</i>	149
<i>MABs targeting CCR5 receptor</i>	150
<i>PRO 140</i>	150
<i>Ibalizumab</i>	151
Integrase inhibitors	151
<i>Raltegravir (Isentress)</i>	151
<i>Elvitegravir</i>	152
<i>Dolutegravir</i>	152
<i>S/GSK1265744</i>	153
<i>LEDGINS</i>	153
Design of fusion inhibitor peptides against enfuvirtide-resistant HIV-1	153
Maturation inhibitors	154
Blocking of pre-integration complex translocation	154
Immune enhancers	154
Pyrimidinediones.....	155
Combinations of drugs for AIDS.....	156
<i>Truvada</i>	156
<i>Raltegravir, enfuvirtide, and darunavir</i>	156
Other innovative antiviral approaches against HIV/AIDS.....	156
A filtration device for HIV-1 as an adjunct to the immune system	156
Anti-HIV therapies based on editing enzymes	156
Anti-HIV activity of drugs that stimulate cholesterol efflux	157
Antiviral hyperactivation-limiting therapeutics	157
ATR kinase as a target for anti-HIV drug discovery.....	157
Blocking of HIV budding by DC-SIGN protein.....	157
Drugs from natural sources	158
Enhancing immune response by blockade of PD-1 receptor	158
IL-2 as adjunct to antiretroviral therapy	159
In vitro evaluation of antiviral drug activity	159
Methods for sustaining antiviral activity	159
Microbicidal agents for local application in HIV/AIDS	160
<i>Investigational microbicides against HIV and their limitations</i>	160
<i>CCR5 receptor blockers</i>	161
<i>PSC-Rantes and recombinant chemokine analogs</i>	161
<i>HIV-1 entry inhibitor griffithsin as a topical microbicide</i>	162
<i>Nanotechnology-based topical microbicides</i>	162
<i>Next generation microbicides for HIV</i>	162
<i>Vaginal application of anti-retroviral drugs against HIV</i>	162
Nanoviricides for HIV/AIDS	163
Prophylactic measures to prevent HIV infection	163
Selective targeting of ITK to block multiple steps of HIV replication	164
Cell therapy for HIV/AIDS	164
hESCs converted to T-cells for treatment of HIV infection	164
Transplantation of genetically modified hematopoietic cells	165
Transplantation of genetically modified T cells	165
Overlapping Peptide-pulsed Autologous Cells.....	165
Gene therapy strategies in HIV/AIDS.....	166
Gene editing for HIV-1.....	166
Inhibition of HIV-1 replication by lentiviral vectors	167
VRX496-T (Lexgenleucel-T).....	167
Insertion of protective genes into target cells	168
Use of genes to chemosensitize HIV-1 infected cells.....	168
Autocrine interferon- β production by somatic cell gene therapy	168
Intracellular immunization in HIV	168
<i>Engineered cellular proteins such as soluble CD4s</i>	168

<i>Intracellular antibodies</i>	169
<i>Selection of T-cell vaccine antigens</i>	169
<i>Glycoprotein 120 as target for neutralizing HIV-1 antibodies</i>	169
<i>Anti-rev single chain antibody fragment</i>	169
HIV/AIDS vaccines	170
<i>Cell-based vaccines for HIV</i>	170
<i>Delivery of HIV vaccine by an adenoviral vector</i>	171
<i>DNA vaccines for HIV/AIDS</i>	172
<i>Epitope-based DNA vaccines against HIV</i>	173
<i>Gene transfer for HIV vaccination</i>	173
<i>Recombinant HIV proteins</i>	173
<i>Vaccination after discontinuation of antiretroviral treatment</i>	173
Innovations in HIV/AIDS vaccine	174
<i>Attenuated rabies virus-based vaccine for HIV</i>	174
<i>Dendritic cell-based vaccine for HIV</i>	174
<i>DermaVir</i>	175
<i>Early control of HIV by an effector memory T cell vaccine</i>	175
<i>Immunogens for inducing broadly neutralizing antibodies</i>	175
<i>MVA nef vaccine</i>	176
<i>Peptide-based vaccine for HIV</i>	176
<i>Personalized vaccine for HIV</i>	176
<i>RV144 HIV vaccine trial</i>	177
<i>Transdermal nanoparticles for immune enhancement in HIV</i>	177
<i>Vaccine to prevent HIV entry at the mucosal level</i>	177
Limitations and future of HIV vaccines	178
Antisense approaches to AIDS	179
<i>Antisense oligodeoxynucleotides</i>	179
<i>Antisense efforts with PNA constructs</i>	179
<i>RNA decoys</i>	180
<i>Ribozymes</i>	180
RNAi applications in HIV/AIDS	181
<i>A multiple shRNA approach for silencing of HIV-1</i>	181
<i>Aptamer-mediated delivery of anti-HIV siRNAs</i>	181
<i>Bispecific siRNA constructs</i>	182
<i>Role of the nef gene during HIV-1 infection and RNAi</i>	182
<i>siRNA-directed inhibition of HIV-1 infection</i>	182
<i>Synergistic effect of snRNA and siRNA</i>	184
<i>Targeting CXCR4 with siRNAs</i>	184
<i>Targeting CCR5 with siRNAs</i>	184
<i>Concluding remarks on RNAi approach to HIV/AIDS</i>	185
Companies involved in developing gene therapy for HIV/AIDS	185
Conclusions regarding gene therapy of HIV/AIDS	186
Testing for new anti-HIV therapies	186
Personalized approach to management of HIV	187
Differences in response of the body to HIV	187
Variations in action of drugs on HIV	187
<i>Drug-resistance in HIV</i>	188
<i>PhenoSense® to test HIV drug resistance</i>	188
<i>Role of biomarkers in management of HIV/AIDS</i>	188
<i>Role of diagnostic testing in management of HIV</i>	189
<i>Prevention of adverse reactions to antiviral drugs</i>	189
<i>Nanoviricides as a personalized approach to HIV</i>	190
Concluding remarks and future	190
9. Hepatitis Viruses	193
Introduction	193
Hepatitis delta virus infection	193
Hepatitis A virus infection	193
Hepatitis E virus infection	194
Epidemiology	194
Structure of the HEV	194
Treatment of HEV infection	194
<i>Ribavirin</i>	194
<i>HEV vaccines</i>	195
Epidemiology of HBV	195
Pathogenesis of HBV-induced liver disease	195
Current approaches to management of HBV	196
Entecavir	197
Adefovir dipivoxil	197
Telbivudine	197
Pegylated interferon-alpha	198

Limitations of current therapies and needs of HBV	198
Personalized management of HBV	198
Innovations in the management of HBV	199
Tenofovir disoproxil fumarate	199
Hepatitis B immune globulins	199
<i>Nabi-HB</i>	199
<i>HepaGam B</i>	200
Hepatitis B vaccine composed in a novel nanoemulsion adjuvant	200
Innovative pharmaceuticals for HBV	200
<i>AGX-1009</i>	200
<i>Clevudine</i>	201
<i>Helioxanthin analog 8-1</i>	201
<i>HepDirect prodrugs</i>	201
Monoclonal antibodies for HBV.....	201
RNAi-based therapy of HBV	202
Personalized treatment of hepatitis B	202
Concluding remarks and future prospects of management of hepatitis B	203
Epidemiology of HCV.....	203
HCV characteristics.....	203
Pathomechanism of HCV infection	204
Mechanism of HCV entry	204
HCV and the immune system	204
Mechanism of HCV replication and response to interferon.....	204
Current approaches to management of HCV	205
Interferon therapy for HCV.....	205
Limitations of current HCV therapies	205
Novel approaches to HCV.....	206
HCV protease inhibitors	207
<i>ABT-450</i>	207
<i>Boceprevir</i>	207
<i>Combined daclatasvir and asunaprevir</i>	207
<i>Faldaprevir</i>	208
<i>Narlaprevir</i>	208
<i>Sofosbuvir</i>	208
<i>Simeprevir</i>	208
<i>Small molecule HCV protease inhibitors</i>	209
<i>Telaprevir</i>	209
Innovations in interferon therapy for HCV	210
<i>AlbIFN-α2b</i>	210
<i>Directed evolution of gene-shuffled IFN-α for treatment of HCV</i>	210
<i>GEA007.1</i>	210
<i>Omega DUROS</i>	210
<i>PEG-IFN-λ</i>	211
<i>Personalizing interferon therapy of HCV</i>	211
Innovative ribavirin-based treatments	212
<i>Targeted delivery of hemoglobin-ribavirin conjugate for HCV</i>	212
<i>Taribavirin</i>	212
Nucleoside polymerase inhibitor.....	212
<i>Deleobuvir</i>	212
<i>Valopicitabine</i>	213
Host cell targets for hepatitis C therapy	213
<i>SP-10</i>	213
NS5a inhibitors	214
<i>Ledipasvir</i>	214
NS5b inhibitors.....	214
Novel combination of a protease inhibitor and a NS5a inhibitor	214
<i>Zepatier</i> TM	214
Compounds targeting HCV receptor E2	215
Cyclophilin inhibitors	215
<i>Alisporivir</i>	215
Methylene blue	216
Naringenin	216
Nitazoxanide	216
Cyclosporine and analogs as anti-HCV agents.....	217
Clemizole and HCV	218
RNAi-based approaches to HCV	218
<i>Use of adenoviral vectors for RNAi</i>	218
<i>siRNAs for HCV</i>	218
<i>Limitations and drawbacks of siRNA therapy for HCV</i>	219
<i>Role of miRNA in viral infections</i>	220
<i>miR-122 antagonists</i>	220

Gene therapy for HCV.....	220
Vaccines for HCV	221
<i>HCV vaccine based on viral vectors to boost T cell memory</i>	221
<i>Vaccine based on neutralizing antibodies to HCV</i>	221
Clinical trials of HCV therapeutics.....	221
Limitations to the development of effective anti-HCV therapeutics	222
<i>Causes of treatment failure in chronic hepatitis C</i>	222
<i>HCV drug resistance</i>	223
Personalized management of HCV infection	223
Role of sequencing in personalized management of HCV	224
Concluding remarks about HCV therapy	225
Drug combinations for HCV	225
IFN-free combinations for HCV	225
Search for new drugs for HCV.....	226
Future needs in HCV therapy	226
10. Miscellaneous Commercially Important Virus Infections	229
Introduction	229
Herpes viruses	229
Neuroinvasive herpesviruses	229
Herpes simplex virus	229
Treatment of HSV-1	229
<i>Acyclovir</i>	229
<i>Vaccines for HSV</i>	230
<i>Antisense therapy for HSV-1</i>	230
Herpes simplex virus 2 and genital herpes	231
<i>Famciclovir</i>	231
<i>Pritelivir</i>	231
<i>Intravaginal microbicial agents for HSV-2</i>	231
<i>Vaccines for HSV-2</i>	232
Herpes simplex keratitis	232
Herpes simplex encephalitis	233
Limitations of current HSV therapies	233
<i>Genomic diversity of HSV-1 as a cause of failure of vaccines</i>	233
Herpes zoster virus	234
<i>Herpes zoster and chicken pox</i>	234
<i>Epidemiology of herpes zoster</i>	234
<i>Treatment of herpes zoster</i>	234
<i>Herpes zoster vaccines</i>	235
Epstein-Barr virus	236
Latent herpes virus infection	236
Cytomegalovirus	236
Current treatment of CMV	237
<i>Brincidofovir (CMX001)</i>	237
<i>Valganciclovir hydrochloride</i>	237
<i>Limitations of current treatment and future prospects</i>	237
Letermovir	237
T cell therapy for CMV	238
Vaccines for CMV	238
Gene therapy of CMV	239
Antisense approach to CMV	239
siRNA treatment of CMV	240
Human papilloma virus	240
Epidemiology.....	240
Vaccines for HPV.....	240
<i>Gardasil</i>	241
<i>Cervarix</i>	241
<i>DNA vaccine VGX-3100</i>	241
<i>GTL001 and GTL002</i>	242
<i>Vaccine based on fusion proteins of HPV envelope</i>	242
<i>Limitations of HPV vaccines</i>	242
Antivirals for HPV.....	243
<i>Imiquimod</i>	243
Novel approaches against HPV.....	243
<i>Intrabody strategies for the treatment of HPV</i>	243
<i>A novel peptide to inhibit HPV</i>	244
<i>Heat shock protein-based antivirals</i>	244
Respiratory syncytial virus	245
Epidemiology.....	245
Current management of RSV	245
<i>Palivizumab</i>	245

MDT-637.....	245
GS-5806.....	246
RNAi approach to RSV.....	246
Other approaches to RSV antivirals.....	247
Vaccines for RSV.....	247
BCG as a vaccine against RSV.....	247
Oral DNA vaccine for RSV.....	247
Neutralizing antibodies against preactive form of hRSV_F protein.....	247
Challenges for development of RSV antivirals.....	248
Other respiratory viruses.....	248
Parainfluenzavirus type 3.....	248
Human metapneumovirus.....	248
Gastrointestinal viruses.....	249
Noroviruses.....	249
Potential for development of antiviral agents against noroviruses.....	249
Vaccines against noroviruses.....	250
Concluding remarks.....	250
11. Viruses with High Impact but Low Commercial Significance.....	251
Introduction.....	251
Chikungunya fever.....	251
Chikungunya antiviral therapy.....	252
Chikungunya vaccines.....	252
Enteroviruses.....	252
Enterovirus 71.....	252
Coxsackie virus.....	253
Japanese encephalitis.....	253
Vaccines for JE.....	253
Parvovirus.....	254
Polyomavirus JC.....	254
Rabies.....	255
Rabies vaccines.....	255
Recombinant viral vaccines for rabies.....	256
DNA vaccine against rabies.....	256
Rabies immune globulin.....	256
Monoclonal antibodies for rabies.....	256
NanoViricides approach for rabies.....	257
Protein-protein interactions as targets for antirabies drug discovery.....	257
siRNA-based approach against rabies.....	257
The Milwaukee protocol for rabies.....	258
Rotavirus.....	258
Epidemiology.....	258
Rotavirus genome.....	258
Vaccines against rotavirus.....	259
Viral hemorrhagic fevers.....	260
Bas-Congo virus associated with acute hemorrhagic fever.....	261
Crimean-Congo hemorrhagic fever.....	261
Dengue.....	262
Epidemiology.....	262
Antivirals in development.....	263
Dengue vaccines.....	264
Elimination of dengue vector mosquitoes by fungus.....	266
Genetic elimination of dengue vector mosquitoes.....	266
Ebola virus.....	266
Pathogenesis and diagnosis of Ebola virus.....	267
Sequencing of the Ebola genome.....	267
Antiviral approaches to Ebola virus infection.....	268
Antivirals for Ebola based on inhibition of RNA polymerase.....	269
Cell entry blockers as antivirals for filoviruses.....	269
Development of RNAi-based antiviral drugs for Ebola.....	270
EbolaCide.....	270
Monoclonal antibody immunotherapy for Ebola.....	270
Vaccines for Ebola.....	271
Ebola whole virus vaccine.....	273
Companies developing antivirals against Ebola.....	274
Concluding remarks and future.....	274
Human hanta viruses.....	275
Lassa fever.....	275
Marburg hemorrhagic fever.....	276
Therapies in development against Marburg virus.....	276
Yellow fever.....	277

<i>Vaccines for yellow fever</i>	277
<i>Sequencing of Aedes aegypti genome and control of yellow fever</i>	277
West Nile virus	278
Epidemiology.....	278
Pathogenesis.....	278
Treatment of West Nile neuroinvasive disease	279
Vaccines against WNV	279
Innovative treatments for WNV.....	279
Zika virus	280
Introduction to Zika virus.....	280
ZIKV in the USA.....	280
Clinical features of ZIKV	281
Molecular epidemiology of ZIKV	281
Molecular diagnosis of ZIKV infection.....	281
Neurological complications of ZIKV infection.....	281
<i>Microcephaly</i>	282
<i>Guillain-Barré syndrome</i>	282
Prevention and treatment of ZIKV infection	283
<i>Antiviral agents against ZIKV</i>	283
<i>Preventive measures against ZIKV infection</i>	283
<i>Vaccines for ZIKV</i>	284
<i>WHO views on challenges in management of ZIKV</i>	285
Western equine encephalitis	286
Tick-borne encephalitis	286
TBE vaccines	287
Human coronaviruses	287
SARS.....	287
<i>Therapeutic approaches to SARS</i>	288
<i>MABs for SARS</i>	288
<i>siRNA treatment of SARS</i>	289
Middle East respiratory syndrome coronavirus	289
<i>Development of therapeutics for MERS-CoV</i>	291
<i>MERS vaccines</i>	291
<i>Future directions for management of MERS</i>	292
Measles	292
Zoonotic viral infections	293
Vaccines for zoonotic viral diseases	293
Virus bioterrorism and biowarfare	293
Small pox as a biological weapon	294
<i>Status of small pox vaccination</i>	294
Strategies against virus bioterrorism and biowarfare	295
<i>Increasing resistance by stimulating innate immune mechanisms</i>	295
<i>Nanoviricides for combating viral bioterrorism</i>	295
Concluding remarks	296
12. Markets for Antivirals	297
Introduction	297
Markets according to disease	297
Influenza market	297
HIV/AIDS market.....	298
Hepatitis B and C markets.....	299
<i>Economics of care of hepatitis C and impact on the market</i>	299
Markets for diseases with low commercial significance	299
Markets according to products and approaches	300
Market values of monoclonal antibodies for viral diseases	300
Market values of vaccines for viral diseases	300
Markets for vaccines against HPV.....	301
Research investment and potential markets for HIV/AIDS vaccines	301
Markets for other antiviral vaccines	301
Markets according to geographical areas	301
Emerging markets for antiviral therapeutics	302
Geographical distribution of HIV/AIDS market	303
Unmet needs in antivirals	303
Policies regarding conquered viral diseases	304
Future of polio vaccine.....	304
Policies concerning HPV vaccine for prevention of cervical cancer	305
<i>HPV vaccine in developing countries</i>	305
Future prospects of innovative approaches	306
US Government support of antiviral efforts.....	307
<i>US Government support for R & D in avian influenza vaccines</i>	307
<i>US Government support for developing anti-bioterrorism agents</i>	307

The European Union support of antiviral research	308
<i>European Commission's research support for anti-HIV/AIDS programs</i>	308
<i>European Commission's support anti-influenza programs</i>	309
Collaboration of biotechnology companies with big pharma	310
Strategies for marketing	310
13. Companies	311
Introduction	311
Top companies	311
Profiles of pharmaceutical companies	312
Profiles of biopharmaceutical companies with antiviral products	328
Profiles of antiviral drug companies	415
Profiles of viral vaccine companies	444
Collaborations	524
14. References	531

Tables

Table 1-1: A practical classification of viruses	20
Table 1-2: Viruses causing encephalitis	27
Table 1-3: Vaccines vs therapeutics for viral diseases	28
Table 1-4: Historical landmarks in the development of antiviral therapies	29
Table 2-1: Classification of antiviral strategies	31
Table 2-2: Viral vs cellular targets for discovery of antivirals	32
Table 2-3: Viruses amenable to antisense oligonucleotides	45
Table 2-4: Inhibition of viral replication by RNAi	47
Table 3-1: Types of vaccines for viral diseases	54
Table 4-1: Role of nanobiotechnology in virology	63
Table 5-1: Methods of delivery of antiviral agents	71
Table 5-2: Role of nanotechnology for improving delivery of antivirals	78
Table 5-3: Commercially available liposomal antiviral vaccines	81
Table 6-1: SWOT of monoclonal antibodies	85
Table 6-2: SWOT of agents that prevention viral entry into cells	86
Table 6-3: SWOT of drugs interfering with intracellular replication	86
Table 6-4: SWOT of protease inhibitors	86
Table 6-5: SWOT of integrase inhibitors	86
Table 6-6: SWOT of maturation inhibitors	86
Table 6-7: SWOT of neuraminidase inhibitors	87
Table 6-8: SWOT of targeting Toll-like receptors (TLRs)	87
Table 6-9: SWOT of topical antivirals agents against viral infections	87
Table 6-10: SWOT of gene therapy, antisense oligonucleotides, RNAi	87
Table 6-11: SWOT of vaccines	87
Table 6-12: SWOT of NanoViricides	88
Table 7-1: Anti-influenza approaches	96
Table 7-2: Antiviral drugs used for influenza	96
Table 7-3: Various approaches to production of influenza vaccines	111
Table 8-1: Drugs in clinical development for HIV/AIDS	146
Table 8-2: Strategies for gene therapy of AIDS	166
Table 8-3: Classification of HIV/AIDS vaccines in clinical trials	170
Table 8-4: Companies involved in developing gene therapy for HIV/AIDS	185
Table 9-1: Innovations in the treatment of HBV	199
Table 9-2: Innovations for management of HCV	206
Table 9-3: Antiviral agents for HCV targeting host cells	213
Table 9-4: HCV drugs in clinical trials	222
Table 10-1: Methods of delivery of acyclovir	230
Table 11-1: Antiviral strategies against Ebola virus infection	268
Table 11-2: Companies developing antiviral products against Ebola	274
Table 11-3: ZIKA vaccines in development	285
Table 11-4: Strategies against virus bioterrorism and biowarfare	295
Table 12-1: Worldwide market for all antiviral approaches 2016-2026	297
Table 12-2: Markets for antiviral drugs according to virus infections 2016-2026	297
Table 12-3: Markets values of all drugs for HIV/AIDS 2016-2026	298
Table 12-4: Market values of monoclonal antibodies for viral diseases 2016-2026	300
Table 12-5: Market values of vaccines for viral diseases 2016-2026	300
Table 12-6: Markets for antiviral drugs according to geographical areas 2016-2026	302
Table 12-7: Markets for antiviral vaccines according to geographical areas 2016-2026	302
Table 12-8: Emerging markets for antiviral drugs according to countries 2016-2026	302
Table 12-9: Emerging markets for antiviral vaccines according to countries 2016-2026	303

Table 13-1: Top antiviral companies	311
Table 13-2: Roche antiviral products in development	318
Table 13-3: Collaborations of antiviral companies	524

Figures

Figure 1-1: Varieties of host and cell responses to viral infections	22
Figure 1-2: Cycle of infection and replication of a retrovirus	24
Figure 1-3: Viral-induced cancer	26
Figure 2-1: An integrated approach to viral diseases	50
Figure 4-1: Schematic representation of NanoViricide attacking a virus particle	67
Figure 7-1: Evolution of mutations associated with virulence/drug resistance in H5N1	93
Figure 7-2: Mechanism of development of resistance to oseltamivir	99
Figure 8-1: Mode of action of some current anti-HIV drugs	137
Figure 8-2: Nanocarrier-mediated siRNA delivery for treatment of HIV/AIDS	184
Figure 9-1: Steps of HBV replication and site of action of various drugs	196
Figure 9-2: Omega DUROS device for interferon delivery in chronic hepatitis C	211
Figure 11-1: Ebola virus	267
Figure 11-2: Strategies for development of ZIKV vaccines	284
Figure 11-3: Transmission and pathogenesis of MERS-CoV	290
Figure 12-1: Unmet needs in antivirals	304